Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
Johnson and Johnson
Medtronic
McKinsey

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Omarigliptin

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Omarigliptin: Patents, clinical trial progress, indications

Omarigliptin is an investigational drug.

There have been 14 clinical trials for Omarigliptin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., British University In Egypt, and [disabled in preview].

There are sixteen US patents protecting this investigational drug and eighty-six international patents.

Recent Clinical Trials for Omarigliptin
TitleSponsorPhase
Omarigliptin & Trelagliptin in Twelve Healthy Egyptian VolunteersBritish University In EgyptN/A
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)Merck Sharp & Dohme Corp.Phase 4
A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)Merck Sharp & Dohme Corp.Phase 3

See all Omarigliptin clinical trials

Clinical Trial Summary for Omarigliptin

Top disease conditions for Omarigliptin
Top clinical trial sponsors for Omarigliptin

See all Omarigliptin clinical trials

US Patents for Omarigliptin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Omarigliptin   Start Trial Process for preparing chiral dipeptidyl peptidase-IV inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Omarigliptin   Start Trial Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Omarigliptin   Start Trial Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Omarigliptin   Start Trial Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes Merck Sharpe & Dohme Corp. (Rahway, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Omarigliptin

Drugname Country Document Number Estimated Expiration Related US Patent
Omarigliptin Japan 2017523172 2034-07-21   Start Trial
Omarigliptin World Intellectual Property Organization (WIPO) 2016014324 2034-07-21   Start Trial
Omarigliptin Argentina 074306 2028-11-13   Start Trial
Omarigliptin Australia 2009314191 2028-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.